Clinical Trial Update: Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating BCMA-targeted CAR-T cells for relapsed/refractory multiple myeloma and is currently recruiting. The trial is conducted un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-targeted CAR-T cells

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Multiple Myeloma, Relapsed/Refractory | Phase 2 | Status: RECRUITING